Some people think the benefit of screening is huge, and others say that the reduction in death rates is due primarily to adjuvant therapy, Berry says. No one has known for sure, and although we still don't know for sure, this is the best set of analyses that is possible given the available information., M. D. Anderson News Release

It's unlikely it will be needed this fall, especially if further tests show that one standard shot is good enough to protect people from the virus. But using adjuvant could prove helpful in future years, or if the flu took a turn for the worst, said Dr. Wilbur Chen, a vaccinologist at the University of Maryland's Center for Vaccine Development, who is leading the NIH-sponsored tests.Kelly Brewington, The Baltimore Sun